CAJ | 학술논문

目的：探讨丁苯酞联合依达拉奉治疗进展性脑梗死的临床疗效，并分析其作用机制。方法将78例进展性脑梗死患者按照随机数字表法分为对照组和观察组，每组39例，两组均采用常规治疗，对照组在常规治疗基础上加用依达拉奉，观察组加用丁苯酞软胶囊和依达拉奉，两组均连续用药12 d，对两组患者治疗前后神经功能缺损程度进行评分，评定临床疗效，并观察两组的不良反应情况。结果观察组的总有效率为89．74％，明显高于对照组的66．67％（χ2＝11．672，P＜0．05）。治疗后两组患者NIHSS评分均较治疗前明显下降（t＝11．04、12．88，均P＜0．05），其中观察组下降更为显著，与对照组比较差异具有统计学意义（t＝10.93，P＜0．05））。治疗后观察组纤维蛋白含量、血液黏度及血小板聚集率均明显低于对照组（ t＝6．69、6.22、7．30，均P＜0．05）。结论丁苯酞联合依达拉奉治疗进展性脑梗死疗效确切，能够显著改善患者的神经功能缺损症状，降低纤维蛋白含量、血液黏度和血小板聚集率，值得推广应用。
목적：탐토정분태연합의체랍봉치료진전성뇌경사적림상료효，병분석기작용궤제。방법장78례진전성뇌경사환자안조수궤수자표법분위대조조화관찰조，매조39례，량조균채용상규치료，대조조재상규치료기출상가용의체랍봉，관찰조가용정분태연효낭화의체랍봉，량조균련속용약12 d，대량조환자치료전후신경공능결손정도진행평분，평정림상료효，병관찰량조적불량반응정황。결과관찰조적총유효솔위89．74％，명현고우대조조적66．67％（χ2＝11．672，P＜0．05）。치료후량조환자NIHSS평분균교치료전명현하강（t＝11．04、12．88，균P＜0．05），기중관찰조하강경위현저，여대조조비교차이구유통계학의의（t＝10.93，P＜0．05））。치료후관찰조섬유단백함량、혈액점도급혈소판취집솔균명현저우대조조（ t＝6．69、6.22、7．30，균P＜0．05）。결론정분태연합의체랍봉치료진전성뇌경사료효학절，능구현저개선환자적신경공능결손증상，강저섬유단백함량、혈액점도화혈소판취집솔，치득추엄응용。
Objective To investigate the clinical effect of butylphthalide combined with edaravone in the treatment of progressive cerebral infarction and its impact on neurological deficits and hemorheology .Methods 78 patients with progressive cerebral infarction were divided into the control group and observation group according to the random number table ,39 cases in each group .The two groups were given conventional treatment ,the control group was given edaravone on the basis of the conventional treatment ,while the observation group was given butylphthalide soft capsules and edaravone .All of the patients were given continuous medication for 12d.The degree of neurological deficit score,clinical assessment efficacy and adverse reactions were compared between the two groups .Results The total effective rate of the observation group was 89.74%,which was significantly higher than 66.67% of the control group(χ2 =11.672,P<0.05).After treatment,the NIHSS scores were decreased significantly (t=11.04,12.88,all P<0.05),that in the observation group was declined more significantly ,compared with the control group ,the differ-ence was statistically significant (t=10.93,P<0.05).After treatment,the fibrin level,blood viscosity and platelet aggregation of the observation group were significantly lower than those of the control group ( t=6.69,6.22,7.30,all P<0.05).Conclusion Butylphthalide combined with edaravone in the treatment of progressive cerebral infarction can significantly improve the patients'neurological symptoms ,reduce fibrin level ,blood viscosity and platelet aggrega-tion,and its security is good ,which is worth to be applied in clinical .